Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1199 results
March 2022
-
Media ReleaseNovartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapyInitial agreement covers reservation of state-of-the-art cell and gene facility in Morris Plains, U.S. HER 2 targeted CAR-M cell therapy is tested in initial trials for the treatment of solid…
-
Media ReleaseNEJM publication of Novartis Kisqali® data shows longest median overall survival ever reported in HR+/HER2- advanced breast cancerMONALEESA-2 results show a statistically significant more than one-year increase in survival for women with HR+/HER2- postmenopausal aBC when using Kisqali plus letrozole compared to letrozole alone…
-
Media ReleaseNovartis, Voyager Therapeutics reach license option agreement for next-generation gene therapy vectors for neurological diseasesNovartis gains target-specific access to next-generation AAV capsids that could be used for three diseases of the central nervous system, with options for two additional targets Agreement builds…
-
Media ReleaseNovartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General MeetingShareholders approve 25th consecutive dividend increase to CHF 3.10 (+3.3%) per share for 2021; representing a 3.9% yield1 and approximately 57% payout of free cash flowShareholders confirm Dr. Joerg…
-
Media ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaireLes actionnaires approuvent la 25e augmentation consécutive du dividende qui passe à CHF 3.10 (+3,3%) par action pour 2021; représentant un rendement de 3.9%1 et une distribution du free cash-…
-
Media ReleaseAktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gutDie Aktionäre genehmigen die 25. Dividendenerhöhung in Folge auf CHF 3.10 (+3,3 %) pro Aktie für 2021; dies entspricht einer Rendite von 3.9 %1 und einer Ausschüttung von rund 57 % des freien…
-
Media ReleaseNovartis peer-reviewed safety and tolerability data further strengthens Kesimpta’s (ofatumumab) favorable benefit-risk profile in patients with relapsing multiple sclerosisMultiple Sclerosis Journal has published data from the ALITHIOS open-label extension study which provide a robust picture of the continuous safety data for Kesimpta, showing it was well tolerated in…
February 2022
-
Media ReleaseSandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicineLenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines1,4Cost savings from Lenalidomide Sandoz can expand treatment options for…
-
Key ReleaseNovartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021Ad hoc announcement pursuant to Art. 53 LR Q4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD) IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +12…
-
Key ReleaseNovartis: a enregistré, en 2021, une croissance du chiffre d’affaires net à un chiffre dans le milieu de la fourchette, une expansion de la marge et une avancée du robuste pipelineAnnonce événementielle selon l’art. 53 RC Chiffre d’affaires net du 4e trimestre en hausse de +6% (tcc1, +4% USD) et résultat opérationnel core croissant de +12% (tcc1, +9% USD) Innovative…
-
Key ReleaseNovartis erzielt 2021 ein Umsatzwachstum im mittleren einstelligen Bereich, verbessert die Margen und treibt die solide Pipeline voranAd-hoc-Mitteilung gemäss Art. 53 KR Im vierten Quartal stieg der Umsatz um +6% (kWk1, +4% USD), das operative Kernergebnis wuchs um +12% (kWk, +9% USD) Innovative Medicines steigerte den…
Pagination
- ‹ Previous page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- …
- 100
- › Next page